StreetInsider.com Pre-Open Movers 12/26
More News related to ANX
- ADVENTRX Pharmaceuticals Reports Third Quarter Financial Results
- Trading Review for Adventrx Pharmaceuticals Inc. Issued by Beacon Equity
- ADVENTRX Pharmaceuticals to Present at the BIO Investor Forum on October 29
- Adventrx (ANX) Comments on Recent Financial Activity, AMEX Listing, and Denner Resignation
- ADVENTRX Provides Business Update Following Recent Financing Activity
More News related to CPAK
- StreetInsider.com Pre-Open Movers 12/26
- CPAC, Inc. (CPAK) to be Acquired by Buckingham Capital Partners for $8.65 Per Share
- 06/23 StreetInsider.com Unusual 11 Mid-Day Movers
- Largest Volume Increases of Note 05/26: NWIR, CPAK, HUMC, GCA, COO
More News related to DRRX
- DURECT Corporation (DRRX) Reports Smaller-Than-Expected Loss on Higher Revenues
- DURECT Corporation Announces Third Quarter 2009 Financial Results
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
- DURECT Corporation to Participate in Upcoming Healthcare Conferences
More News related to General News
- Ambac Financial (ABK) Shares Sink on Bankruptcy Warnings
- Priceline.com (PCLN) Trading Lower after Downgrade
- Las Vegas Sands (LVS) to Restart Macau Casino Projects
- Benmosche Threatens to Resign as AIG (AIG) CEO
- Mangers of Bear Stearns Hedge Fund Collapse Acquitted
StreetInsider.com Pre-Open Movers:
Telik (Nasdaq: TELK) 72% LOWER; Announced negative results from three separate Phase 3 clinical trials of its investigational drug TELCYTA. ASSIST-1 and ASSIST-2 Trials Did Not Achieve its Primary Endpoint, ASSIST-3 Compromised.
ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) 15% HIGHER; its Investigational New Drug (IND) application for the clinical development of its proprietary cancer drug ANX-530 has been accepted by the FDA. In taking this action, the FDA acknowledged the suitability of the Company's clinical study protocol to establish the bioequivalence of ANX-530, and Navelbine. Navelbine is an anti-cancer agent approved for use in non-small cell lung cancer.
Fuwei Films Co., Ltd. (Nasdaq: FFHL) 13% HIGHER; last week's IPO extends gains
EpiCept Corporation (Nasdaq: EPCT) 10% HIGHER; entered into a license agreement with DURECT Corporation (Nasdaq: DRRX) pursuant to which it has granted DURECT the exclusive, worldwide rights to certain of EpiCept's intellectual property for a transdermal patch containing bupivacaine for the treatment of back pain.
Taylor Devices Inc. (Nasdaq: TAYD) 6% HIGHER; Taiwan earthquake, tsunami
InterMune Inc. (Nasdaq: ITMN) 5% HIGHER; continues Friday's 29% move. Wachovia and Leerink Swann upgrades
Escala Group Inc. (Nasdaq: ESCL) 4% LOWER; continues to give back last week's gains.
Mamma.com Inc. (Nasdaq: MAMA) 1.5% LOWER; continues to give back last few weeks of gains.
CPAC, Inc. (NASDAQ: CPAK) INDICATED HIGHER; entered into a definitive merger agreement under which affiliates of Buckingham Capital Partners II, L.P. will acquire all the outstanding shares of CPAC, Inc., for approximately $42.8 million, plus the assumption of approximately $6.7 million in debt. Under the terms of the merger agreement, CPAC shareholders will receive $8.65 in cash for each share of CPAC common stock they hold.
Related Categories
General NewsSpecial Reports
Stocks Mentioned
+0.01
-6.44Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
